{"analyses":[{"ciLowerLimit":"52.1","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"100","groupDescription":"This Kaplan-Meier estimate is the conditional probability of event-free survival among study participants at 12 and 24 months.","groupIds":["OG000"],"nonInferiorityType":"OTHER","paramType":"Kaplan-Meier estimate","paramValue":"76.2"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Month 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Event free survival is the time to treatment failure from the time of study enrollment to tumor progression, tumor recurrence, death from any cause or occurrence of a second malignant neoplasm.","groups":[{"description":"Participants with juvenile pilocytic astrocytomas or optic pathway gliomas receiving PEGINTRON based on their weight (1 mcg/kg/dose) once a week, for up to two years","id":"OG000","title":"PEGINTRON"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Month 12, Month 24","title":"Number of Participants Meeting Event Free Survival Criteria","type":"SECONDARY","unitOfMeasure":"Participants"}